MONISTAT-DERM (miconazole nitrate) by Sight Sciences is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1974.
Drug data last refreshed 34m ago · AI intelligence enriched 6d ago
MONISTAT-DERM is a topical miconazole nitrate cream indicated for vulvovaginal candidiasis. It exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. The drug is absorbed minimally following topical administration, with clinical efficacy demonstrated in multi-center trials.
Product is approaching loss of exclusivity with only 2 linked job openings, indicating a small, potentially contracting team focused on legacy brand maintenance.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT-DERM at Sight Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MONISTAT-DERM offers limited career growth given the product's LOE-approaching status and small linked job count (2 positions). Career opportunities are concentrated in manufacturing and IT support, with minimal exposure to commercial brand building, medical affairs, or pipeline development.
2 open roles linked to this drug